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Abstract 
Objectives: Acute gastroenteritis (AG) is a usually self-limiting, but common disease worldwide. In Europe, incidence 
estimates range from 0.3–1.5 AG episodes/person-year. For Switzerland, available information on AG is restricted to 
notifiable foodborne diseases and findings from research studies starting at primary care level. The aims of this 1-year, 
population-based prospective cohort study are to assess the incidence, burden of disease, aetiology and socio-eco-
nomic impact of AG in the Swiss general population. Additionally, the prevalence of bacterial gastrointestinal patho-
gens and bacteria harbouring antimicrobial resistances in the asymptomatic population shall be assessed.
Results: Weekly follow-up of the cohort consisting of 3000 participants will provide incidence estimates of AG. Fur-
thermore, information collected will be used to assess risk factors for experiencing an episode of AG, to explore deter-
minants for help seeking, and to characterise the socio-economic impact of AG including absence from work and 
inability to perform daily activities. Aetiology of AG is determined by investigating stool samples from symptomatic 
participants. Finally, stool samples from participants collected during an asymptomatic period will be used to assess 
the prevalence of enterohaemorrhagic E. coli, Campylobacter spp., Salmonella spp. and Shigella spp. as well as of resist-
ance to different antibiotics (extended-spectrum beta-lactamase-, fluoroquinolone- and carbapenemase-resistance).
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resistance, Switzerland
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Introduction
Acute gastroenteritis (AG), manifesting with signs and 
symptoms of diarrhoea, vomiting, abdominal pain or 
cramps, fever, dehydration, nausea and/or loss of appe-
tite, is usually self-limiting, but leads to a considerable 
burden of disease, health system use and socio-economic 
impact. Studies in several European countries estimated 
the incidence of AG at 0.3–1.5 episodes per person and 
year [1–14]. Furthermore, it was found that a consider-
able 11% of patients with infectious enteritis develop 
post-infectious irritable bowel syndrome [15, 16]. Inci-
dence of AG for Switzerland is assumed to be compara-
ble, but data is limited to notifiable pathogens reported 
to the Federal Office of Public Health (FOPH) based on 
the Epidemics Act. Several studies from other European 
countries have shown that (i) only 6.4–37.8% of all AG 
episodes lead to consultation of a physician [1–9, 11, 12, 
14], and (ii) 0.2–1.8% of episodes are reported to national 
surveillance systems [1, 11, 14]. These proportions are 
highly variable between countries and pathogens due to 
different help seeking behaviour, case management and 
surveillance systems [17]. From a study in the Swiss Sen-
tinel Surveillance Network, Sentinella, we estimated that 
around 175,000 individuals consulted a physician due 
to AG in Switzerland in 2014 [18]. Around 12% of cases 
were asked to submit a stool specimen and hence, could 
potentially—if positive—be reported to the National 
Notification System for Infectious Diseases (NNSID) 
if their sample tested positive for a notifiable pathogen 
and was reported by the diagnostic laboratory. However, 
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the proportion of AG patients consulting a physician is 
currently not known for Switzerland. Consequently, 
inference from the above-mentioned frequencies and 
proportions to the incidence and burden of AG at popu-
lation level is not possible.
Therefore, the present study primarily aims at measur-
ing the incidence of acute gastroenteritis in the general 
population in Switzerland. Secondary objectives are to 
describe the burden of disease and the socio-economic 
impact of AG, to assess its aetiology and to investigate 
the frequency of selected risk exposures. Finally, the 
carriage rate of selected pathogenic bacteria and bacte-
ria harbouring selected antibiotic resistances among the 
“healthy” (non-diarrhoeal) population in Switzerland is 
assessed.
Main text
Study design and methodology
A 1-year, prospective cohort study is conducted to deter-
mine the incidence of AG in the general population in 
Switzerland. The study will assess signs and symptoms of 
AG and exposure to selected risk factors (incl. antibiotic 
use). In case of symptoms, the help seeking behaviour of 
patients, inability to work or to perform usual daily activ-
ities, perceived illness experience and socio-economic 
consequences of the illness will be explored. Further-
more, the aetiology of AG is investigated by examining 
stool samples from a subsample of participants report-
ing gastrointestinal symptoms. Finally, the prevalence 
of selected bacterial gastrointestinal pathogens (entero-
haemorrhagic Escherichia coli [EHEC], Campylobacter, 
Salmonella and Shigella) and bacteria with selected anti-
biotic resistances (extended-spectrum beta-lactamase 
[ESBL], carbapenemase, fluoroquinolone, and mobilised 
colistin resistance [mcr]-1) is assessed among partici-
pants during an asymptomatic period.
Study setting, recruitment process and eligibility
A representative sample of the Swiss population will be 
requested from the Federal Statistical Office. The cohort 
is recruited by postal mail. The procedure for cohort 
recruitment is shown in Fig. 1. Invitation letters include 
a study information document, an informed consent 
form, a contact information questionnaire (for obtain-
ing participants’ contact details and for selection of the 
preferred language and means of communication) and a 
short screening questionnaire to assess study eligibility. 
Eligibility criteria for participating in the study are: liv-
ing in Switzerland; speaking German, French or Italian; 
age ≥ 14  years; not suffering from cancer of the bowel, 
irritable bowel syndrome, Crohn’s disease, ulcerative 
colitis, cystic fibrosis, coeliac disease or another chronic 
illness with symptoms of diarrhoea or vomiting.
Data collection and management
Upon return of the signed informed consent and the 
completed contact information and screening question-
naires, eligible study participants receive a baseline ques-
tionnaire, a stool sampling kit including an information 
and instruction sheet on stool sampling, and the first 
weekly questionnaire. The content of each questionnaire 
is summarised in Table 1. Participants will continuously 
receive the weekly questionnaire during 1 year (52 weeks; 
Fig.  2). Participants receive an additional questionnaire 
(“illness questionnaire”) in case of reporting gastrointes-
tinal signs and symptoms. Furthermore, participants are 
advised to immediately report occurrence of diarrhoea 
and/or vomiting actively to the study team by phone, 
BUGS cohort recruitment 
Representative population 
sample from FSO 
N=tbd 
Invitation letter, 
study info incl. informed consent, contact 
information sheet (preferred way of 
communication; e-mail, phone, address, 
language), screening questionnaire 
(eligibility criteria) 
N= ~15’000 
Assessment: eligible & 
signed informed consent? 
N= ~5000 
Baseline questionnaire (demographics, dietary 
habits, medication, chronic diseases, permanent 
& long-term exposure risks),  
stool sampling kit with 
information on stool sampling 
N= ~3500 
Random 
selection 
Eligible & Enrolled 
N= ~3500 
Returned as undeliverable 
N= ~1500 
Not eligible or not willing 
to participate 
N= ~1500 
Fig. 1 Operational flowchart of cohort recruitment for the burden 
of gastroenteritis in Switzerland (BUGS) study. FSO, Federal Statistical 
Office; tbd, to be defined
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e-mail or SMS (during the day, including weekends) 
(Figs. 2 and 3). This “active reporting system” is used to 
select AG episodes for microbiological investigation 
based on a pre-defined algorithm considering moderate 
and severe cases of illness as defined by Riddle et al. [19]. 
In case the study subject’s AG episode is selected, the 
study team will advise him/her to use the stool sampling 
kit received at the beginning of the study and send a stool 
sample to the study laboratory as fast as possible. After 
sending in a stool sample, the participant’s stool sampling 
kit will be replaced. The list of diagnostic tests performed 
on stool samples from symptomatic participants is pro-
vided in Table 1.  
Each week, a pre-defined number of randomly selected 
participants (see sample size calculation) will receive a 
stool sampling kit to send in a stool sample immediately. 
Those stool samples will be tested for selected patho-
genic bacteria and presence of certain antibiotic resist-
ances with the aim to assess respective prevalences in the 
asymptomatic population (Table 1). The stool sample will 
be discarded if the participant reported diarrhoea with 
or without vomiting in the 4 weeks preceding sampling. 
Sampling is conducted weekly throughout the observa-
tion period to account for potential seasonal differences 
in prevalence. Each participant is selected at most once 
for “asymptomatic sampling”.
All questionnaires apart from the contact information 
and screening questionnaires will be available in elec-
tronic- and paper-format. By default, participants will 
receive an e-mail containing a personalised link to the 
electronic questionnaires. However, during recruitment, 
they may opt for paper-based questionnaires sent by 
postal mail. LimeSurvey, an open source software set-up 
on a secured server at our institution (Swiss TPH), will be 
used for electronic data collection. The software allows 
completion of the questionnaire in a standard internet 
browser using desktop or laptop computers, tablets or 
smartphones.
Electronic questionnaires will be programmed to 
require an answer to ensure completeness of the data 
collected but will include an option “I do not want to 
answer” or “not applicable” (where appropriate) in order 
to prevent a forced-choice bias.
Paper questionnaires are entered by study personnel 
at the study centre using a LimeSurvey data entry mask 
which is slightly adapted from the one used by par-
ticipants (e.g. containing an additional field “no answer 
given” for each mandatory question). A sample of 10% 
of paper questionnaires is entered twice for data quality 
BUGS observation period 
Weekly questionnaire 
(occurrence of symptoms, short-term exposure risks) 
n= ~3000 
*52 weeks/cycles (N= ~156’000) 
Illness questionnaire 
(illness experience, health 
seeking, direct medical, 
direct & indirect non-
medical costs) 
N= ~3000 
Yes No 
“Take stool 
sample” 
N= ~1200 
Stool sample kit with 
letter and information on 
stool sampling, stool 
sample questionnaire 
n=40 
*52 weeks/cycles  
(N= ~2000) 
Symptoms? 
Active reporting 
“I have diarrhoea”  
(occurrence of 
diarrhoea/vomiting) 
N= ~3000 
Stool sample to 
laboratory 
N= ~1200 
Stool sample 
to laboratory 
N= ~2000 
Random sample 
Fig. 2 Flowchart of cohort observation period for the burden of gastroenteritis in Switzerland (BUGS) study
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control. Discordant results are checked against paper 
originals. A full double entry is conducted for the “con-
tact information questionnaire” as correct address details 
are crucial for successfully contacting participants.
Quality control of data from study laboratories (stool 
sample results) will be with the diagnostic laboratories, 
operating according to their standard operating pro-
cedures in their daily routine. The study team will only 
check plausibility of the data and values.
Electronic data are stored on secured network drives 
accessible only by the study team. Data on the network 
drive is backed-up regularly, according to institutional 
policy. Electronic data is stored in original file formats 
and in comma-separated values (csv) format, where 
appropriate, to ensure long-term accessibility.
Sample size calculation
We calculated the minimal sample size based on differ-
ent parameter assumptions for comparisons between 
two distinct groups and for within-subject comparisons 
between two distinct periods. Underlying formulas and 
results are provided in Additional file 1.
A cohort size of 3000 individuals is envisaged to 
allow analysis of secondary outcomes and comparisons 
between groups and to assert enough power in case 
assumptions were too optimistic based on the different 
sample size calculations. We plan to start the observation 
period with a cohort size of 3500 individuals in order to 
achieve an average cohort size of 3000 after withdrawals 
and loss to follow-up during the 52 weeks study period. 
Assuming a participation rate of 25% (including loss of 
people not meeting the eligibility criteria) and a loss to 
follow-up of 20%, 15,000 people will be contacted ini-
tially. For planning purposes, we assume an average 
cohort size of 3000 throughout the 1-year observation 
period.
The sample size (n) needed to reach a specific relative 
precision (ε) for the microbiological outcomes in asymp-
tomatic participants (prevalence of antibiotic resistances 
and selected pathogenic bacteria) was calculated using 
the following formula (based on [20]):
For the prevalence of ESBL, a relative precision of 
20% is envisaged at a 95% confidence level. Assuming 
a prevalence (P) of 5–6% (based on [21, 22]), a sample 
size of 1505–1825 is needed. Considering that the pre-
vious prevalence estimates are from groups of poten-
tially higher prevalence than the general population 
(staff members of meat-processing companies with 
likely higher exposure risk; and primary care patients), 
we plan to investigate 2000 samples. Hence, every week 
40 subjects are randomly selected. Given the very low 
prevalence of Carbapenemase-resistance (0.1%; personal 
n =
1.96
2
∗ (1− P)
ε2 ∗ P
Diarrhoea/
vomiting 
Active reporting: 
“I have diarrhoea” 
(call/SMS/e-mail) 
“Take stool 
sample” (if 
episode 
selected) 
Participant receives 
& completes weekly 
questionnaire 
Did you have GI 
symptoms 
Monday to 
Sunday last 
week? 
Processing of weekly 
questionnaire (e.g. 
data entry) 
In case of 
symptoms: Illness 
questionnaire 
Fig. 3 Timeline from occurrence of symptoms until sending of illness questionnaire for the burden of gastroenteritis in Switzerland (BUGS) study. 
GI, gastrointestinal
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communication) and mcr-1 (not found in 1000 samples; 
personal communication) it is questionable whether 
these resistances will be found at all in our cohort. The 
prevalence of fluoroquinolone-resistance in E. coli has 
not yet been investigated in the asymptomatic Swiss 
population. Fluoroquinolone resistance prevalence in 
E. coli is at around 20% based on resistance data gener-
ated during routine medical care [23]. Hence, using the 
same sample size as for ESBL (N = 2000) should allow for 
an estimate with a relative precision of at least 20% even 
if the prevalence in the general Swiss population is some-
what lower than 20%.
The presence of pathogenic bacteria (EHEC, Campylo-
bacter spp., Salmonella spp., and Shigella spp.) can only 
be investigated in 1600 samples of asymptomatic partici-
pants (of 2000 collected) due to financial constraints. For 
this investigation, the main interest is on EHEC preva-
lence in asymptomatic people. Considering that this 
prevalence is expected at around 7–10% (personal com-
munication) a sample size of 1600 will still allow for a 
relative precision of 15–18%.
Approach to analysis
Definition of AG disease episode
The primary outcome of our study is presence or absence 
of an AG episode and the incidence of AG in the general 
population. For this purpose, an episode of AG is clas-
sified according to a modified version of the definition 
suggested by Majowicz et al. [24]: a case of AG is an indi-
vidual with ≥ 3 loose stools in 24 h, with or without vom-
iting, but excluding those (a) with cancer of the bowel, 
irritable bowel syndrome, Crohn’s disease, ulcerative coli-
tis, cystic fibrosis, coeliac disease, or another chronic ill-
ness with symptoms of diarrhoea, or (b) who report their 
symptoms were due to drugs, alcohol, or pregnancy. An 
episode is defined to begin on the first day and end on the 
last day of reported diarrhoea and/or vomiting, followed 
by a diarrhoea- and vomiting-free period of 3 days [25].
Statistical analysis
Data cleaning and analysis will be conducted with the 
statistical software Stata and/or R. All steps performed to 
clean and analyse the data are documented in scripts (R) 
or do-files (Stata).
The cohort will be characterised in terms of demo-
graphic characteristics, health status, dietary habits and 
permanent or long-term risk exposures as reported at 
baseline. Similarly, cohort participants lost to follow-up 
will be compared to those remaining in the cohort.
The primary outcome defined at the level of person-
week is presence or absence of an AG episode. Risk 
factors for experiencing an episode of AG will be deter-
mined using multivariable mixed logistic regression 
analyses with the individual included as a random effect. 
A basic multivariable model including the biologi-
cally most plausible variables, region and season will be 
defined a priori. Generalised estimating equation  (GEE) 
models will be considered in case of convergence issues 
of the mixed logistic regression models.
Secondary analyses will include calculating the 
incidence of AG as the number of AG episodes per 
person-year under observation and the incidence of gas-
trointestinal signs and symptoms (including episodes 
not fulfilling the case definition of AG). Furthermore, 
transient risk factors for experiencing an episode of AG 
will be explored in uni- and multivariable mixed logistic 
regression models, including the individual as random 
effect. Exposure information from the week preceding 
the AG episode will be used. Determinants for presenting 
to the health system (pharmacies, primary care, special-
ists or hospitals) in case of AG are also investigated, again 
using uni- and multivariable mixed logistic regression 
models (with the individual as random effect). Predic-
tor variables include signs and symptoms, and perceived 
severity of AG, demographic characteristics (age, sex, 
occupational status), co-morbidity, and type of health 
insurance. Additionally, the socio-economic impact such 
as absence from work, inability to perform usual daily 
activities and the need for care by family members or 
friends related to AG disease episodes will be described.
Results from stool sample investigations from symp-
tomatic participants will be used to estimate pathogen-
specific incidence rates of AG.
Finally, the prevalences of bacteria harbouring ESBL-, 
carbapenem- and fluoroquinolone-resistance, and of 
EHEC, Campylobacter, Salmonella and Shigella in the 
asymptomatic population are calculated.
Ethical considerations
Health-related personal data and stool samples from 
participants are collected for this study. Therefore, 
the study is subject to the Federal Act on Research on 
Human Beings and requires ethical approval. Approval 
will be sought from the responsible local ethical 
committee(s) for a non-clinical trial study with mini-
mal risks. All participants will be asked for written 
informed consent before enrolment. The study will be 
conducted according to the principles of Good Epide-
miological Practice [26] and the Declaration of Helsinki 
[27].
Participants will be advised to seek health care as 
they would do without participating in this study. Simi-
larly, it will be emphasised that investigation of stool 
samples in the framework of this study does not replace 
stool sample investigation potentially initiated by their 
health care provider. Results of stool investigations of 
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symptomatic participants conducted as part of this 
study are obtained with a time delay due to study logis-
tics. Hence, microbiological results will be known to 
the study team too late to affect treatment considering 
the short disease duration of most AG episodes and, 
therefore, will not be communicated to participants or 
their physicians.
Participants are informed if antibiotic resistances are 
identified in their stool samples during an asymptomatic 
period and advised to inform their physician in case of 
illness.
Operational issues
Data confidentiality and personalisation
Ideally, questionnaires should be anonymous as soon as 
they contain health-related personal information. How-
ever, we must be able to link the different questionnaires 
completed by each study participant. To minimise the risk 
that unauthorised people are able to link the participants’ 
names to their questionnaire data, we plan to implement 
several measures: each participant is given a person iden-
tification code (“person ID”) as well as a questionnaire 
identification code (“questionnaire ID”). The person ID 
is used in all files/data sets containing personal informa-
tion. The questionnaire ID is used in all files/data sets 
containing information obtained from questionnaires or 
from laboratory testing. The key file, linking the person 
ID and the questionnaire ID will be password protected 
and stored separately from the other data sets. Access to 
this key file will be limited to the principal investigator, 
the study coordinator and an additional person (substi-
tute of the study coordinator). For paper-based question-
naires, both codes (person ID and questionnaire ID) are 
printed on the empty questionnaires. However, as soon 
as receipt of the completed questionnaires is registered 
in the study centre, the person ID will be removed (cut 
off). In order to avoid that both codes are easily visible 
and recognised as such by unauthorised persons, one of 
the codes (the person ID) is printed in directly readable 
format (Arabic letters and numerals) and the other code 
is printed as a QR- or bar-code. Also, the two codes are 
not labelled with “person ID” or “questionnaire ID”. For 
electronic questionnaires only the “questionnaire ID” will 
be used and no names are stored in LimeSurvey (where 
questionnaire data is entered and stored during the entire 
data collection phase). In order to complete the question-
naire, participants will receive an e-mail including a link 
to the questionnaire containing the questionnaire ID.
Active reporting system needed
For investigating the aetiology of AG, stool samples need 
to be obtained quickly after disease onset as AG is usually 
a short, self-limiting disease. Therefore, the information 
on signs and symptoms obtained through the weekly 
questionnaire is too much delayed to be the basis for 
selection of episodes for aetiological investigation (espe-
cially in those completing the paper-based question-
naires; Fig. 3). We expect reporting delays of 1–13 days in 
those completing electronic questionnaires and of at least 
3–10 days (best case scenario) for paper-based question-
naires which will severely impact the likelihood to detect 
pathogens. To address this limitation, we plan to set up 
an “active reporting system” for participants (see “Data 
collection and management”). These parallel ways of col-
lecting data on diarrhoea and vomiting have advantages 
and disadvantages: on the one hand, we can compare 
reporting completeness of the two methods. On the other 
hand, participants are required to actively think of the 
study when experiencing signs and symptoms, and have 
to report their symptoms twice—potentially increasing 
reporting fatigue and reporting bias due to sensitisation. 
Further, the active reporting system requires that study 
personnel being able to communicate in all three study 
languages is on call every day, including weekends and 
public holidays.
Limitations
Our study will be subject to limitations. Participation bias 
is likely to occur. Considering the rather long observation 
period (1 year with weekly follow-ups), a certain amount 
of participants will be lost to follow-up or withdraw from 
the study; these participants might differ from those 
completing the entire follow-up period. Similarly, report-
ing fatigue might occur, especially in those experiencing 
more than one episode of AG. However, all those biases 
and limitations are unavoidable in cohort studies and 
their mitigation is difficult. To address reporting fatigue, 
we consider establishing a project newsletter to give par-
ticipants feedback about interim results of the study and 
additional information related to the topic to highlight 
the importance of their contribution to research. Inverse 
probability weighting will be considered if characteris-
tics of our final cohort differ from those of the general 
population.
Furthermore, compliance in actively reporting signs 
and symptoms as well as in providing stool samples is 
crucial. Therefore, its importance will be emphasised 
repeatedly to study participants. We suspect that compli-
ance might be associated with the (perceived) severity of 
the disease episode. However, we can only try to assess 
this bias at the end of the study by comparing data from 
active reporting/stool sampling and data from weekly 
questionnaires.
Recall bias and telescoping have been described as 
major challenges in studies on AG. We believe that this 
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bias might not be a notable problem in our study consid-
ering the rather short recall period of 1 week.
Participants travelling will still receive the electronic 
questionnaire but those completing paper-based ques-
tionnaires will be able to complete the questionnaire only 
once they returned. This might lead to different compli-
ance and recall bias in those two groups. On the other 
hand, it provides an opportunity to assess potential dif-
ferences in results between the two methods.
Additional file
Additional file 1. Sample size calculations and underlying formulas for 
the BUGS study. Sample size calculations for the burden of gastroenteritis 
in Switzerland (BUGS) study based on different parameter assumptions, 
including derivation of underlying formulas.
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